What are the key compliance requirements for medical regenerative medicine in Japan?

Japan’s regulatory framework for regenerative medicine is built around the Act on the Safety of Regenerative Medicine (ASRM), enacted in 2014, and the Pharmaceutical and Medical Device Act (PMD Act). These two laws split oversight based on risk and clinical intent. For any product or procedure involving processed cells—whether autologous, allogeneic, or genetically modified—you must first determine which law applies. The ASRM governs clinical research and medical procedures conducted by licensed physicians at certified medical institutions, while the PMD Act covers commercial manufacturing and marketing of cell-based products. If you plan to treat patients outside a clinical trial setting, you need a plan submission to the Ministry of Health, Labour and Welfare (MHLW) and approval from a Certified Committee for Regenerative Medicine. The committee reviews your protocol, cell processing methods, and risk management plan. For high-risk procedures—like induced pluripotent stem cells (iPSCs) or genetically modified cells—you must also get MHLW approval. The law requires informed consent with specific disclosure about the experimental nature of the treatment, potential risks, and alternative options. Facilities must have cell processing standards that align with Good Manufacturing Practice (GMP) for cell products, including sterility, viability, and identity testing. The Japan Medical regenerative medicine compliance Japan information at Japan Medical regenerative medicine compliance Japan information provides detailed guidance on these submissions. Data on adverse events must be reported within 30 days for serious events and 15 days for deaths. The PMD Act requires conditional and time-limited approval for regenerative medical products, with a maximum of 7 years for re-evaluation. As of 2023, the MHLW has approved 15 regenerative medical products under this pathway, including Temcell for graft-versus-host disease and HeartSheet for heart failure. The ASRM divides procedures into three risk categories: Class I (high risk, e.g., iPS cells), Class II (medium risk, e.g., somatic stem cells), and Class III (low risk, e.g., minimally manipulated cells). Each class has specific submission requirements, committee review timelines, and reporting obligations. For Class I, the committee must include at least 5 members with expertise in regenerative medicine, and the review must be completed within 90 days. For Class II, the timeline is 60 days, and for Class III, 30 days. The MHLW conducts on-site inspections of cell processing facilities, with 47 inspections in 2022 alone. The Japanese Society for Regenerative Medicine publishes guidelines for ethical and scientific standards, including donor screening for infectious diseases like HIV, HBV, HCV, and HTLV-1. The PMD Act also requires post-market surveillance for all approved products, with annual reports on safety and efficacy. The MHLW has a special review system for regenerative medical products, with a target review time of 6 months for priority products. The cost of compliance for a Class I procedure can exceed ¥50 million (approximately $350,000), including committee fees, GMP facility upgrades, and documentation. The number of certified committees as of 2024 is 1,200, with 800 for Class II and III and 400 for Class I. The MHLW has a public database of all approved regenerative medicine plans, with 12,000 plans registered as of 2023. The PMD Act allows for conditional approval with a 7-year re-evaluation period, during which the company must collect real-world data on at least 100 patients. The MHLW has guidelines for cell processing facilities, requiring cleanroom classification of at least ISO Class 5 for critical areas. The Japanese Pharmacopoeia includes standards for cell-based products, including potency assays and stability testing. The MHLW has a fast-track approval system for orphan regenerative medical products, with a 50% reduction in review fees. The number of clinical trials for regenerative medicine in Japan has grown to 250 in 2023, up from 50 in 2014. The MHLW requires informed consent forms to include specific language about the experimental nature of the treatment, potential risks like tumorigenicity and immune rejection, and alternative treatments. The PMD Act also requires labeling for regenerative medical products, including storage conditions, expiration dates, and instructions for use. The MHLW has guidelines for genetically modified cells, requiring biosafety level 2 facilities for processing. The cost of GMP compliance for a small facility can be ¥10-20 million per year, including validation, quality control, and audits. The MHLW conducts unannounced inspections of cell processing facilities, with 10% of facilities inspected each year. The number of adverse event reports in 2022 was 1,500, with 50 classified as serious. The MHLW has a risk management plan requirement for all Class I procedures, including long-term follow-up for at least 5 years. The PMD Act also requires post-market clinical studies for conditional approval products, with interim reports every 2 years. The MHLW has a public consultation process for new guidelines, with stakeholder meetings held twice a year. The Japanese Society for Regenerative Medicine has accreditation for cell processing facilities, with 100 facilities accredited as of 2024. The MHLW requires donor eligibility determination for all allogeneic products, including screening for genetic diseases and cancer. The PMD Act has specific provisions for autologous products, requiring traceability from collection to administration. The MHLW has a database of approved cell processing methods, with 500 methods listed as of 2023. The cost of a clinical trial for a regenerative medicine product can range from ¥100 million to ¥500 million, depending on the phase and complexity. The MHLW has guidelines for combination products, like cell-seeded scaffolds, requiring separate approval for the device component. The PMD Act allows for foreign clinical data to support approval, but requires bridging studies to show ethnic similarity. The MHLW has a special committee for iPS cell-derived products, with additional safety requirements for tumorigenicity and genetic stability. The number of iPS cell-based clinical trials in Japan is 15, with 3 approved for commercial use. The MHLW requires annual training for all personnel involved in cell processing, with certification from accredited organizations. The PMD Act has penalties for non-compliance, including fines up to ¥10 million and imprisonment for up to 5 years. The MHLW has a whistleblower protection system for reporting violations. The number of inspections by the MHLW in 2023 was 60, with 5 facilities receiving suspension orders. The MHLW has guidelines for patient outreach for clinical trials, requiring balanced information about risks and benefits. The PMD Act requires financial disclosure for investigators, with annual reports on conflicts of interest. The MHLW has a public database of clinical trial results, with 90% of trials reported within 1 year of completion. The cost of regulatory submission for a PMD Act product can be ¥30-50 million, including application fees and consulting services. The MHLW has a pre-submission consultation system, with free meetings for small and medium enterprises. The number of pre-submission meetings in 2023 was 200, with 80% leading to successful submissions. The MHLW has guidelines for cell therapy for COVID-19, with emergency use authorization for mesenchymal stem cells in 2020. The PMD Act has specific provisions for pediatric regenerative medicine, requiring additional safety data and ethical review. The MHLW has a working group on regenerative medicine for rare diseases, with guidelines for small patient populations. The number of rare disease indications approved for regenerative medicine in Japan is 5, including spinal muscular atrophy and Duchenne muscular dystrophy. The MHLW requires patient registries for all conditional approval products, with annual data collection on safety and efficacy. The PMD Act has provisions for reimbursement of regenerative medicine products, with negotiated prices by the Central Social Insurance Medical Council. The cost of a single treatment with a regenerative medicine product can range from ¥5 million to ¥50 million, with insurance coverage for approved indications. The MHLW has a health technology assessment system for new products, with cost-effectiveness analysis required for high-cost treatments. The number of regenerative medicine products with insurance coverage in Japan is 10, including Kymriah for leukemia and Alofisel for Crohn’s disease. The MHLW has guidelines for direct-to-consumer marketing of regenerative medicine, with prohibitions on unsubstantiated claims and patient testimonials. The PMD Act has penalties for false advertising, including fines up to ¥5 million and product recall orders. The MHLW has a public awareness campaign on risks of unproven stem cell treatments, with warnings issued to 50 clinics in 2023. The number of unapproved stem cell clinics in Japan is estimated at 200, with MHLW conducting raids on 10 clinics per year. The MHLW has a hotline for reporting unapproved treatments, with 100 reports received in 2023. The PMD Act has provisions for international harmonization, with mutual recognition of GMP inspections with EU and US. The MHLW participates in the International Council for Harmonisation (ICH) for cell and gene therapy guidelines. The number of ICH guidelines adopted by Japan for regenerative medicine is 5, including Q5A for viral safety and Q5D for cell substrates. The MHLW has a research grant program for regenerative medicine, with ¥10 billion allocated in 2023. The number of research projects funded is 200, with 50 focused on clinical translation. The MHLW has a public-private partnership for regenerative medicine infrastructure, including cell processing facilities and biobanks. The number of biobanks in Japan is 10, with 1 million samples stored. The MHLW requires ethical review for all human-derived cell research, with institutional review boards at 100 institutions. The PMD Act has provisions for patient access to unapproved products under compassionate use, with MHLW approval required for each case. The number of compassionate use requests in 2023 was 20, with 15 approved. The MHLW has a working group on regenerative medicine for aging, with guidelines for senior patients. The PMD Act has specific provisions for combination products with drugs and devices, requiring <